Page 24 - Huck Institutes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

As the coronavirus pandemic has evolved over the past year, Penn State’s testing strategy for the virus has, too. This spring, Penn State increased random testing to 2% of its students, faculty and staff a day compared to 1% a day in the fall semester. According to Suresh Kuchipudi, Penn State professor of immunology and microbiology, testing 2% of the population a day improves the detectability of the coronavirus rather than stopping transmission entirely. Penn State’s consensus is that it’s impossible to create a testing system that completely halts the virus — much of r...

A team of Penn State researchers is using wastewater testing to track the rise and fall of the COVID-19 virus in the State College area. WPSU's Anne Danahy

Researchers awarded $1.5M to create stem cell predictive model The challenge of reproducing adult stem cells plagues the regenerative medicine industry. Penn State biomedical engineering researchers seek to find solutions through computer modeling. Image: iStock/@anusorn nakdee Researchers awarded $1.5M to create stem cell predictive model Mariah Chuprinski February 10, 2021 UNIVERSITY PARK, Pa. — Stem cells are the building blocks of the body, according to Penn State researchers. Though similar to one another at their origins, stem cells take on unique characteristics as they mature, becom...

Researchers investigate the duration of the immune response to SARS-CoV-2 The optimal timeframe for donating convalescent plasma for use in COVID-19 immunotherapy, which was given emergency use authorization by the Food and Drug Administration in August 2020, is within 60 days of the onset of symptoms, according to a new Penn State-led study. The research also reveals that the ideal convalescent plasma donor is a recovered COVID-19 patient who is older than 30 and whose illness had been severe. Millions of individuals worldwide have recovered from COVID-19 and may be eligible for participatio...

 E-Mail UNIVERSITY PARK, Pa. -- The optimal timeframe for donating convalescent plasma for use in COVID-19 immunotherapy, which was given emergency use authorization by the Food and Drug Administration in August 2020, is within 60 days of the onset of symptoms, according to a new Penn State-led study. The research also reveals that the ideal convalescent plasma donor is a recovered COVID-19 patient who is older than 30 and whose illness had been severe. "Millions of individuals worldwide have recovered from COVID-19 and may be eligible for participation in convalescent plasma donor programs...